drugset / Trial / NCT01057277
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
Phase 1
Terminated
3 enrolled
Howard Safran
Memorial Hospital of Rhode Island · collabRhode Island Hospital · collabRoger Williams Medical Center · collabThe Miriam Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be safely administered with cisplatin, and concurrent radiotherapy, for patients with locally advanced, inoperable, squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-05
- Completion
- 2011-06
Outcome
Outcome not reported
Stopped (Business): “Pharmaceutical co- re aligned their specialties- no longer will fund H\&N ca”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | — |